XYZ

Nestmedic S.A. is expanding into new markets

3 January 2018

Pregnabit makes another step on the way to global commercialization. Thanks to a grant from PARP, it will be presented at the top trade fairs in Europe, Asia, South America and the Middle East.

Nestmedic has concluded an agreement with PARP (the Polish Agency for Enterprise Development) that covers the activities under the Go To Brand programme. We now have a strong support for our international expansion process. The PARP grant will allow Nestmedic to present its solutions to key business partners and distributors in Europe, Asia, South America, the United States and the Middle East.

This year, international expansion is the key aspect of Nestmedic’s development strategy. The global demand for telemedicine is rapidly growing. We are following this trend and have already signed agreement with partners in Germany and Kenya. We are actively seeking new partnerships. The grant of more than PLN 0.5 million from PARP will definitely open new markets for us, says Patrycja Wizińska-Socha, M.D., CEO at Nestmedic.

In April, Pregnabit will be presented in Asia at the Medical Fair in New Delhi. Brazil, where the annual expenditure on telemedicine reaches USD 744 million (Frost&Sullivan 2017), will see Pregnabit in May at the Hospitalar Fair in São Paulo.

We will also travel on an economic mission to the United Arab Emirates (UAE). It is a country with impressive population growth and high expenses on healthcare. We will be there at the end of January at the Arab Health Fair, starting the process of Pregnabit commercialization in this part of the world, adds Anna Skotny, M.D., General Manager and Co-founder of Nestmedic.

As part of the Go To Brand programme, Pregnabit will also be presented at Florida International Medical Expo in the United States. In the U.S., the expenses on newborn children reach USD 45 billion per year, which makes the American market the top of the list.

In the U.S., there are 0.8 million teleconsultations per year and telemedicine is treated the same way as traditional medicine by insurance companies in more than 30 states, says Anna Skotny.